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EXECUTIVE SUMMARY 
 
Introduction 
This paper summarises key information on New Psychoactive Substances (NPS) 
and evidence gaps. Data on Scotland is presented in the context of UK and 
international evidence. 
 
Definition of NPS 
In the UK, the Advisory Council on the Misuse of Drugs (ACMD) defines ‘new 
psychoactive substances’ as: “psychoactive drugs which are not prohibited by the 
United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 
1971, and which people are seeking for intoxicant use”. Although not scheduled 
under the UN drug control conventions, a number of the NPS mentioned in this 
paper are now controlled in the UK (e.g. mephedrone, BZP, NBOMe and Benzofury). 
 
Main types of NPS available 
The number of NPS available is constantly changing and growing which makes it 
difficult to identify levels and risks of use and for health and enforcement agencies to 
respond. NPS can contain legal substances, illegal substances, or even a mixture of 
both. They can be grouped according to their chemical names, or more usefully, by 
their intended effects on the user (e.g. stimulants). A record number of 81 
substances were detected for the first time in Europe in 2013, up from 73 substances 
in 2012, 49 in 2011, 41 in 2010, and 24 in 2009 (EMCDDA, 2014).  However, this 
increase in numbers should be treated with caution, given that it may in part reflect 
increasing efforts and capability to detect NPS, and that most of these drugs have 
not been seen in the UK. 
 
Prevalence of use 
Evidence from national surveys shows that use of NPS amongst the general adult 
population (e.g. those aged 16-59) is relatively low compared with use of other illicit 
drugs. However, use amongst younger age groups and some sub-sections of the 
population is higher. This pattern also applies in Scotland, where mephedrone is the 
most common NPS, used by 1.6% of all 16-24 year olds in the last year, but by only 
0.4% of all adults. Cannabis is still the most commonly used illicit drug in Scotland, 
taken by 5.1% of all adults in the last year (2012/13 Scottish Crime and Justice 
Survey). 
 
Supply 
In Scotland, there were 213 seizures of NPS (mephedrone and ketamine) by police 
forces in 2012/131. This was around 1% of the overall number of Class B and C drug 
seizures in Scotland. NPS have been seized in most countries across the world, but 
there are regional variations. Most NPS originate from Asia, followed by Europe, the 
Americas, Africa and Oceania. The internet plays an important role in the supply of 
NPS, with 651 internet shops identified in Europe in 2013 (EMCDDA, 2014). 
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 There were also 215 ‘other class B’ and 125 ‘other class C’ drug seizures in 2012/13. We know that 
some of these were also NPS, but no breakdown by drug type is currently provided. 
Health implications 
Evidence is limited, but indications are that NPS can cause a range of physical and 
psychological symptoms (from kidney failure to psychosis) that are just as serious as 
for other illicit drugs and can even result in death. In Scotland, over the five years 
from 2009 (when the first figures became available) to 2013, NPS have been 
implicated in 132 deaths (less than 5% of the total number of drug related deaths 
over that period) and in 18 of these an NPS was the only drug implicated (less than 
1% of the total number of drug related deaths). Drug treatment services in the UK 
are seeing increased presentations from people using NPS, and reports of problems 
related to their use. 
 
Responses 
Countries are responding to the growth in demand and supply of NPS, and 
associated harms, in three main ways: enforcement (i.e. through legal controls); 
prevention (i.e. trying to stop people taking them in the first place); and treatment 
(for those experiencing problems from taking NPS).   
 
A range of different actions can be taken to place NPS under legal control.  These 
include: adding new substances to the 1961 or 1971 UN Conventions; using the 
European Early Warning System (EWS) to identify NPS and place them under 
control; and various national measures which involve using consumer safety or 
medicines legislation, extending and adapting existing laws and processes, or 
devising new legislation for new substances. In the UK, the government has control 
of substances under the Misuse of Drugs Act 1971. If a drug is causing sufficient 
concern, the UK Government (following consultation with the Advisory Council on the 
Misuse of Drugs (ACMD)) can issue a Temporary Class Drugs Order for up to 12 
months. The ACMD then has 12 months to investigate and recommend classification 
if they consider there is sufficient evidence. Although these measures may have 
worked to some degree in individual countries, they have left loopholes in the global 
control system which can be exploited by drug manufacturers.  
 
Efforts are also now being made to reduce the demand for NPS by educating 
young people and implementing targeted prevention initiatives.  For example, in 
Scotland information on NPS is provided on the Know the Score website and to 
school children through the Choices for Life initiative.  
 
To date treatment for NPS users who seek formal help is primarily supportive and 
there is limited information on what constitutes appropriate psychosocial treatment 
for this group.  
 
Evidence gaps 
The following are needed in order to inform future policy responses to NPS (both in 
Scotland and more widely): 
 A full assessment of what is known about the scale and patterns of NPS use. 
 Exploration of the nature of the relationship between the new drugs market 
and the established market in controlled drugs. 
 An examination of the short and longer term health impacts of using NPS, and 
other outcomes. 
 A systematic review of the outcomes of the various control systems. 
 Analysis of how current interventions to prevent substance misuse and harms 
may be used for NPS, and consideration of possible new approaches. 
 Evidence of what constitutes appropriate psychosocial treatment for NPS 
users. 
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1 INTRODUCTION 
 
1.1 At a national event on New Psychoactive Substances (NPS) on 17 April 2013, 
the Scottish Government heard from police, health, community and youth 
organisations about the challenges being posed by these new drugs.   A 
major challenge was the need for better information and evidence on NPS, 
and as a first step, this paper summarises the key information that is currently 
available (up to July 2014) and evidence gaps.  The paper is structured 
around the main themes that emerged from the workshop - demand/ 
prevalence of use, supply, impact/ harms, responses (enforcement, 
prevention, and treatment); and evidence gaps. In each section, information 
on what we know about NPS in Scotland is set in the context of information 
from the rest of the UK and internationally. 
1.2 It is important to note that the review does not purport to provide a 
comprehensive and definitive account of the evidence on NPS, but rather 
constitutes a collation of the material which could be identified and accessed 
within a relatively short space of time.  It is hoped that the work will provide a 
foundation upon which new and existing research evidence may be added as 
it becomes available or is identified in the future. 
Definition 
 
1.3 Historically, new psychoactive substances were often referred to as ‘designer 
drugs’ and ‘new synthetic drugs’ although today ‘legal highs’ and ‘new drugs’ 
are the terms used more often. The UK Advisory Council on the Misuse of 
Drugs (ACMD) defines NPS as: “psychoactive drugs which are not prohibited 
by the United Nations Single Convention on Narcotic Drugs or by the Misuse 
of Drugs Act 1971, and which people are seeking for intoxicant use”. Although 
not scheduled under the UN drug control conventions, a number of the NPS 
mentioned in this paper are now controlled in the UK (e.g. mephedrone, BZP, 
NBOMe and Benzofury). 
 
2 MAIN TYPES OF NPS AVAILABLE 
 
Key Findings 
 NPS can contain legal substances, illegal substances, or even a mixture of 
both. 
 They can be grouped according to their chemical names, or, perhaps more 
usefully, by their intended effects on the user (e.g. stimulants). 
 The number of new drugs available is constantly changing and growing – by 
2013, over 300 NPS had been identified in Europe. 
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2.1 The new drugs market involves an overlap of two broad groups of drugs: 
those sold directly on the illicit market with those sold as ‘legal highs’. Some 
NPS are added to or sold in place of established illicit drugs, such as ecstasy, 
and some ‘legal highs’ cross over into the illicit markets once controls are put 
in place (EMCDDA, 2013a). Seized substances marketed as ‘legal highs’ 
have been found to contain controlled drugs – for e.g. a Home Office Forensic 
Early Warning System study found that 19% of internet test purchases of 
‘legal highs’ contained a controlled substance (Home Office, 2012). 
 
 
Number and types of NPS drugs available 
 
2.2 The UNODC report2 (UNODC 2013a) identifies 6 main groups of drugs that 
are present in the NPS market: synthetic cannabinoids (e.g. Spice); synthetic 
cathinones (e.g. mephedrone); ketamine; phenethylamines (e.g. benzofury); 
piperazines (e.g. BZP); and plant based substances.  It also reports on a 7 th 
group of miscellaneous substances that contain recently identified NPS (e.g. 
tryptamines) that don’t fit into any of these groups. Other pharmaceutical 
medications not used within the UK, for example benzodiazepines such as 
Phenazepam, have also been included within the broad definition of NPS by 
the ACMD and the UK National Programme on Substance Abuse Deaths (np-
SAD). As well as these chemical groupings, NPS can also be categorised 
according to their main characteristics, or effects on the user.  For instance, 
DrugWatch has produced ‘The Drugs Wheel’ (www.thedrugswheel.com) 
which groups drugs under: stimulants; empathogens; psychedelics; 
dissociatives; cannabinoids; depressants; and opioids. This also helpfully 
shows which of these drugs are currently controlled in the UK and which are 
still legal. 
 
2.3 The emergence of NPS in the drug markets has gained pace over the last 
decade.  A record number of 81 substances were detected for the first time in 
Europe in 2013, up from 73 substances in 2012, 49 in 2011, 41 in 2010, and 
24 in 2009 (EMCDDA, 2014). The 81 NPS detected in 2013 included: 29 new 
synthetic cannabinoids; 13 new substituted phenethylamines; 7 synthetic 
cathinones; one new piperazine; one new tryptamine; and 30 miscellaneous 
‘other’ substances that do not fit into the main categories above. In total, over 
300 NPS had been identified by member states by mid-2013 (EMCDDA, 
20143).  
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 The information in the report was primarily obtained through an electronic questionnaire on NPS 
which was sent to all Member States and to drug analysis laboratories in July 2012. Responses were 
received from 80 countries (33 from Europe, 23 from Asia, 12 from the Americas, 10 from Africa, and 
2 from Oceania).  
3
 This increase in numbers should be treated with caution, given that: they may in part reflect 
increasing efforts and capability to detect NPS; some drugs may only be seen once and not again; 
and most of these NPS have not been seen in the UK. 
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2.4 The market for NPS is rapidly changing.  Prior to 2008, most countries 
reported ketamine, followed by piperazines and non-controlled 
phenethylamines as NPS. Over the period 2008-2012, most countries 
identified synthetic cannabinoids (e.g. Spice), followed by synthetic 
cathinones (e.g. mephedrone) (UNODC, 2013b).  
 
 
3 PREVALENCE OF USE 
 
Key Findings 
 Evidence from national surveys show that use of NPS amongst the general 
adult population tends to be relatively low compared with use of other illicit 
drugs. 
 However, use amongst younger age groups and some sub-sections of the 
population – e.g. regular night clubbers – may be higher. 
 This pattern also applies in Scotland, where mephedrone was the most 
common NPS, used by 1.6% of all 16-24 year olds in the last year, but by 
only 0.4% of the general adult population (16-59). 
 Cannabis is still the most commonly used illicit drug in Scotland, taken by 
5.1% of all adults in the last year. 
 
Use in the general population 
 
3.1  There are no global estimates of the prevalence of use of NPS in the general 
population, only limited data from a few countries on specific substances and 
sub-populations. Several countries have included NPS in their national drug 
surveys (e.g. Australia, Canada, New Zealand, USA, the UK), but many have 
limitations including: lack of common definitions and of representative 
samples; the large and increasing number of substances regarded as NPS; 
and differences in legislation between countries. Evidence from the few 
surveys that cover the general population suggest that levels of NPS use in 
the general population are generally low. In the UK, our most robust estimates 
of NPS use in the general population come from our national crime surveys.  
 
3.2 In Scotland, the 2012/13 Scottish Crime and Justice Survey reported that 
0.5% of all adults had tried any NPS in the last year (Scottish Government, 
2014).  Mephedrone was the most commonly taken NPS, tried by 0.4% of all 
respondents in the last year.  This compares with 1.7% for cocaine and 1.3% 
for ecstasy. Cannabis is still the most commonly used illicit drug in Scotland, 
taken by 5.1% of all adults in the last year.   
 
3.3 In England and Wales the 2013/14 Crime Survey (Home Office, 2014) found 
that, of adults aged 16-59, 0.6% had taken mephedrone in the last year, 2.3% 
had taken nitrous oxide in the last year and 0.5% had taken salvia in the last 
year. This compares with 2.4% for cocaine 1.6% for ecstasy. Cannabis is still 
the most commonly used illicit drug in England and Wales, taken by 6.6% of 
adults in the last year.   
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3.4 In Northern Ireland, the Drug Prevalence Survey (DPS) 2010/11 found last 
year prevalence of NPS to be 3.5% (NACD, 2012). Again, Cannabis is the 
most commonly used illicit drug in Northern Ireland, taken by 5.1% of adults in 
the last year.   
 
 
Use amongst younger age groups 
 
3.5 Despite use of NPS in the general population being relatively low, surveys 
have found that use in the younger age groups can be considerably higher 
than in other areas of the population. This is presumably why many surveys 
only ask about prevalence of NPS use in younger age groups.  For instance, 
the Eurobarometer Survey (European Commission, 2011) surveyed the 
experiences and attitudes of young people (aged 15-24) in Europe towards 
legal and illegal substances in 2002, 2004, 2008 and 2011 (UNODC, 2013a). 
Evidence from these surveys of young people also reveal regional variations 
in levels and types of NPS use. 
 
3.6 Use of NPS by young people in 2011 appeared to be highest in the USA, 
where it was estimated that around 10% of those aged 15-25 had 
experimented with NPS, compared with around 5% in Europe4. Again, in the 
UK our national crime surveys currently provide the most robust measure of 
prevalence in younger age groups. 
 
3.7 In Scotland, the 2012/13 Scottish Crime and Justice Survey reported that 
2.1% of those aged 16-24 had used any NPS in the last year and last year 
use of mephedrone (the most commonly used NPS) amongst 16 to 24 year 
olds was 1.6% (Scottish Government, 2014). The Scottish Schools 
Adolescent Lifestyle and Substance Use Survey (SALSUS)5 (Scottish 
Government, 2011) found that the use of any NPS by 13 and 15 year olds 
was uncommon (<1%) and 2% of 15 year olds said they had used 
mephedrone in the last year. Results from 2013 SALSUS will be available in 
November 2014. 
 
3.8 The England and Wales Crime  Survey found that in 2010/11, last year use of 
mephedrone (the most commonly used NPS at that time) amongst 16 to 24 
year olds was 4.4% – the same level as the second most commonly used 
drug, cocaine powder. However, by 2013/14 this had fallen to 1.9%. Also in 
2013/14, 7.6% of 16-24 year olds had taken nitrous oxide in the last year, and 
1.8% had taken salvia.  
 
3.9 In Northern Ireland in 2010/11, last year use of mephedrone and ‘legal highs’ 
was 2.2% and 2% respectively amongst adults aged 15-34 (NACD, 2012). 
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 In 2011, the survey included over 12,000 randomly selected young people across the 27 EU 
member states, interviewed by telephone and for the first time it asked about NPS (although small 
sample sizes – 500 people in most countries, 250 in some, means that its findings should be treated 
with caution). 
5
 Results from the 2013 SALSUS will be available in 2014. 
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Use among specific groups of the population 
 
3.10 As well as general population surveys, attempts have been made to measure 
the use of NPS amongst certain sub-groups of the population, such as night 
clubbers. In such populations the use of NPS can be very high and such 
studies provide insights into the harms a drug may have and the potential for 
new drugs to become more widespread (EMCDDA (2013b).   
 
3.11 In late 2013, over 7,0006 people from the UK responded to the annual Global 
Drug Survey. The self-nominating sample were typically in their in 20s and 
30s, well-educated, and about 50% went clubbing at least 4 times a year. 
Some key findings are:  
 Synthetic cannabinoids, remained the most commonly used new psychoactive 
drug (last year use) across the sample.  
 Among regular clubbers in the UK as a whole, mephedrone use in the last 
year fell from 13.8% in 2012, to 12.5% in 2013 (in Scotland, methadone didn’t 
make it into the list of top 20 drugs, based on 631 responses). 
 Ketamine use in the last year also fell, from 31.5% in 2012 to 19.8% in 2013 
(14.7% in Scotland, based on 631 responses). 
 In 2013, nitrous oxide was used by 20.4% UK respondents (10% in Scotland, 
based on 631 responses) in the last 12 months, compared with 27% in 2012. 
 In 2013, 10.9% of all UK survey respondents had taken a mystery white 
powder in the last year (9.3% in Scotland, based on 631 responses) with 
almost 80% stating that they were already intoxicated before taking it. 
 (Winstock, A., 2014) 
 
3.12 The latest in a series of surveys in ‘gay friendly’ nightclubs in South-East 
London (Wood, Hunter, Measham and Darghan, 2012) collected data on use 
of a wide range of NPS via a questionnaire survey. In July 2011, customers 
were asked about life-time use, last month use and/or use on the night of the 
survey/planned use later that night of NPS, cocaine and MDMA/ecstasy. A 
total of 313 individuals were surveyed over 4 nights; 206 (65.8%) had 
previously used a 'legal high'. Mephedrone had the highest prevalence of last 
month use (53.2%) and use on the night of the survey (41.0%). This was 
greater than both cocaine (44.6% and 16.7%, respectively) and 
MDMA/ecstasy (26.9% and 5.8%). There was limited ‘on the night’ use of the 
non-mephedrone 'legal highs': methoxetamine (1.6%) and 1-benzylpiperazine 
(0.6%), Spice/K2 (0.6%) and pipradrols (0.6%).The study concluded that 
although a significant proportion of individuals reported use of NPS, only 
mephedrone had become an established part of the recreational drug scene 
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 The self-selecting nature of the sample, and small numbers in Scotland, mean that results should be 
treated with caution. 
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Use amongst those presenting for specialist drug treatment 
 
3.13 Data from drug treatment services can also provide an indication of levels of 
use of certain substances and the extent to which they are causing problems 
for people using them. So far, treatment data on NPS is almost non-existent, 
but some countries have started to collect data.  For instance, in England and 
Wales, the National Treatment Agency (NTA) has started to collect treatment 
data on ketamine, mephedrone, methamphetamine and GHB. The USA also 
reports on the number of visits to emergency departments that specifically 
involved synthetic cannabinoids (11,406 in 2010) (UNODC, 2013a). 
 
3.14 In Scotland, among individuals attending drug treatment services, 
presentations by people using mephedrone (only been captured by treatment 
statistics in the last 2 years) are small in number. In 2011/12, 1.4% (111 
individuals) of those reporting illicit drug use in the past month, reported using 
it at initial assessment with 35 of these reporting it as their main drug. This is 
down from 2010/11 where 1.6% (133 individuals) reported using Mephedrone, 
with 69 of these reporting it as their main drug (ISD, 2013).  
 
3.15 Presentations at drug treatment services in England by people using 
mephedrone, methamphetamine, ketamine, and GHB have increased in 
recent years (Public Health England, 2013b). The National Treatment Agency 
(NTA) reports that, while overall drug use has fallen, the number of people 
needing treatment for club drugs has risen. Club drug users now make up 2% 
of over 18s and 10% of under 18s in treatment7.  As many as 1 million people 
may use club drugs.  The NTA warns that the delay between people using a 
club drug for the first time and developing a dependency could mean that 
treatment figures continue to rise (National Treatment Agency, 2012). 
 
3.16 Stakeholders in Wales have also reported a rise in referrals related to 
mephedrone and an increase in its use in conjunction with other substances 
(Welsh Government, 2013). In Wales during 2010/11, 88 people accessed 
treatment for mephedrone use with an average age of 21 years (Public Health 
England, 2013a). 
 
 
                                            
7
 Although note that these are people presenting for treatment who have used club drugs, not people 
who have reported them as their primary drug of use. 
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4 SUPPLY 
 
Key Findings 
 In Scotland, there were 213 seizures of NPS (mephedrone and ketamine) by 
police forces in 2012/13. This was around 1% of the overall number of Class 
B and C drug seizures in Scotland. 
 NPS have been seized in most countries across the world, but there are 
regional variations in the types of drugs seized. 
 Most NPS originate from Asia (especially China and India), followed by 
Europe, the Americas, Africa and Oceania. 
 The internet plays an important role in the supply of NPS, with 651 internet 
shops identified in Europe at the last count (EMCDDA, 2014).  
 
Geographical spread 
 
4.1 In Scotland, there were 213 seizures of NPS (mephedrone and ketamine) by 
police forces in 2012/138. This was around 1% of the overall number of Class 
B and C drug seizures in Scotland (Scottish Government, 2014).  
 
4.2 NPS is becoming a global phenomenon. By 2013, NPS had emerged in every 
region of the world – reported by a total of 94 countries worldwide (UNODC, 
2014a).  Of those reported to UNODC between 2008 and 2013, 28% were 
synthetic cannabinoids, 25% synthetic cathinones, and 17% 
phenethylamines. Seizures of synthetic cannabinoids have spread over recent 
years: from three countries in 2009 (Finland, France and Germany) to 16 by 
2011. For synthetic cathinones, (mephedrone being the most widely seized) 
only 2 countries (Finland, Netherlands) reported seizures of over 1kg in 2009, 
rising to 14 in 2011.  Ketamine seizures were already widespread in 2009 (16 
countries) and have remained so, with the biggest seizures being in Asia 
followed by Canada. Phenethylamines seizures are most common in Europe  
- seized in 9 different European countries, as well as New Zealand, from 
2009-2012. Piperazines emerged in almost all regions before 2008 - seizures 
over the last few years have been fairly constant, and mostly in Europe. Plant-
based substances (mainly Khat, kratom and salvia) have been seized in most 
regions and by most countries.  The most significant seizures have been 
reported by Italy for the last four years, followed by New Zealand. Overall, 
trends for the 7 NPS groups fluctuate - whilst seizures of ketamine, 
phenethylamines and piperazines have been fairly stable in recent years, 
experts predict rising trends for synthetic cannabinoids, synthetic cathinones 
and plant-based substances (UNODC, 2013a).  
 
 
Origins of NPS and supply routes 
 
4.3 The primary region from where NPS originate is Asia (especially China and 
India), followed by Europe (including Czech Republic, Hungary, Netherlands, 
Portugal, Spain, Ukraine, UK), the Americas, Africa and Oceania (UNODC, 
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 There were also 215 ‘other class B’ and 125 ‘other class C’ drug seizures in 2011/12. We know that 
some of these were also NPS, but no breakdown by drug type is currently provided. 
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2013a). The most common mode of trafficking is thought to be by air, followed 
by mail. The internet was named as a major source of NPS from all regions, 
having the following advantages for suppliers:  access to a vast number of 
potential users; no need for up-front investment; anonymity; potential to 
bypass the laws of different countries; and enabling NPS to stay ‘under the 
radar’ for longer. It also serves as a source of information e.g. by drugs users 
to find out about new products, experiences and suppliers through forums, 
chat rooms and blogs; and by health and law enforcement authorities to 
expand their knowledge on the subject, e.g. manufacturing processes.   
 
4.4 The most recent EMCDDA snapshot of internet activity on NPS (EMCDDA, 
2014) found that the number of online shops offering NPS for sale in the EU 
has fallen slightly, but is still high, with 651 shops identified in January 2013 
(compared with 693, 314 and 170 in January 2012, 2011, 2010). Three 
natural products – kratom, salvia and magic mushrooms – are the most 
common ‘legal highs’ sold online in Europe, followed by a variety of synthetic 
drugs, mainly cathinones (EMCDDA, 2012).   
 
4.5 The most recent Global Drugs Survey (Winstock, 2014) found that over half 
58.2% of UK respondents had heard of the online drugs marketplace Silk 
Road, and 43.8% of these reported having accessed the site. Of those that 
had heard of Silk Road, 11.4% had taken drugs they'd bought themselves via 
the site and 14.6% said they had consumed drugs purchased on their behalf. 
The most common drug UK respondents purchased on Silk Road was 
cannabis (including synthetic forms), followed by MDMA. LSD, Ketamine and 
2C-B were also popular choices (Winstock, 2014). 
 
 
5 IMPACTS 
 
Key Findings 
 Evidence is limited, but indications are that the health implications of NPS 
can be just as serious as for other illicit drugs including a range of physical 
and psychological symptoms (from kidney failure to psychosis).    
 NPS use can result in death. In Scotland, NPS were implicated in 132 deaths 
between 2009-2013 (although in only 18 of these was an NPS the only drug 
implicated). 
 Drug treatment services in the UK are seeing increased presentations from 
people using NPS, and in reports of problems related to their use. 
 Other impacts associated with NPS are an increase in acquisitive crime and 
the increased involvement of organised crime. 
 
 
Health implications 
 
5.1 Research on the health implications of most NPS is very limited, but what 
evidence there is suggests that the adverse effects can be just as serious as 
for controlled drugs. The recent UNODC report (2013a) gathers together the 
limited available evidence to list the main adverse effects associated with 
  9 
each main NPS groupings. These range from a variety of physical 
symptoms - e.g. cardiovascular problems, hyperthermia (over heating), 
kidney failure, fluid on the lungs, seizures - to psychological disorders, 
including anxiety, agitation, memory loss, depression and psychosis. Health 
impacts will also depend upon whether other drugs and/or alcohol were used 
at the same time as NPS, and the method of use, for e.g. swallowing, 
snorting, injecting, etc. Deaths have been associated with drugs in each of the 
main NPS groups, with the exception of plant based substances, which to 
date have not been directly linked to any fatalities (UNODC, 2013a)9.  
 
5.2 There is currently no evidence of an increase in presentations at drug 
treatment services associated with NPS use in Scotland. However, deaths 
where NPS were found to be present in the body have increased over the 
period, from 4 in 2009, to 113 in 2013.  Deaths where it was reported that one 
(or more) NPS was implicated in the death were lower, but again have 
increased, from 3 in 2009 to 60 in 2013 (totalling 132 over 2009-2013, less 
than 5% of all drug related deaths).  In 2013, 5 out of 60 deaths occurred 
where NPS were identified as being the only substances implicated (a total of 
18 over 2009-2013, less than 1% of all drug related deaths).  
 
5.3 In 39 cases, the only NPS present were benzodiazepines (usually 
phenazepam); in 19 cases, other types of NPS were present (e.g. AMT, BZP, 
PMA or PMMA); there were two deaths for which both benzodiazepine NPSs 
and other types of NPS were present (NRS, 2014).    
 
5.4 2,000 people in treatment in England during 2011/12 cited problems related to 
mephedrone use, over half of whom were under the age of 18. In England 
and Wales, from 2009 to 2012, NPS were implicated in 129 deaths (although 
in only 64 of these was an NPS the only drug mentioned). In 2012, there were 
52 deaths related to NPS, a sharp increase from 29 deaths in 2011. This 
follows a period of stability (23 in 2010, 25 in 2009) after a large rise from nine 
in 2007 to 25 in 2008. (ONS, 2013). 
 
 
Other impacts 
 
5.5 There are indications of other adverse impacts emerging in relation to the use 
and supply of NPS.  For example, the Welsh Government has reported that in 
parts of Wales the increased use of mephedrone may be causing an increase 
in some forms of acquisitive crime – particularly house burglaries. (Welsh 
Government, 2013). 
 
5.6 Recent reports have also noted the potential for organised criminals to 
become more active in the ‘legal high’ market (EMCDDA, 2013a). Reports 
indicate the involvement of organised crime in both the targeting and 
marketing of NPS, although the extent of this is unclear (EMCDDA, 2012).  
 
 
                                            
9
 NB, as the situation is changing so rapidly, this may not now be the case. 
  10 
6 RESPONSES 
 
Key Findings 
 Countries are responding to the growth in demand and supply of NPS in 
three main ways: enforcement; prevention; and treatment. 
 A range of different actions can be taken to place NPS under legal control.  
These include: adding new substances to the 1961 or 1971 UN Conventions; 
using the European Early Warning System (EWS) to identify NPS and place 
them under control; and various national measures which involve using 
consumer safety or medicines legislation, extending and adapting existing 
laws and processes, or devising new legislation for new substances.  
 Although these measures may have worked to some degree in individual 
countries, they leave loopholes in the global control system which can be 
exploited by drug dealers. 
 Efforts are also now being made to reduce the demand for NPS by 
educating young people and implementing targeted prevention initiatives.  
For example, in Scotland information on NPS is provided on the Know the 
Score website and to school children through the Choices for Life initiative. 
 To date treatment for NPS users who seek formal help is primarily 
supportive and there is limited information on what constitutes appropriate 
psychosocial treatment for this group.  
 
6.1 Countries are responding to the growth in demand and supply of NPS, and 
associated harms, in three main ways: enforcement (i.e. through legal controls); 
prevention (i.e. trying to stop people taking them in the first place); and treatment (for 
those experiencing problems from taking NPS).  A brief summary of these types of 
response is given below. 
Enforcement 
 
6.2 NPS fall outside the global drug control system, but some governments have 
adopted either regional or national responses to the issue to protect public 
health. 
 
International drug control system  
 
6.3 A notification can be made to the UN Secretary General to add a new 
substance to any of the schedules of the 1961 or 1971 Conventions. An 
assessment is then made by the World Health Organisation (WHO) which 
may result in the Commission on Narcotic Drugs deciding to add, transfer or 
remove the substance from any of the schedules. This has not happened for 
any NPS yet, but the WHO are looking at a number of substances for risk 
assessment to take to the Commission on Narcotic Drugs (CND) in March 
2015 (Hallam et al, 2014).  
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Regional responses  
 
6.4 So far, the only regional response to the emergence of NPS is the European 
Early Warning System (EWS) of the EU. Established in 1997, and extended in 
2005 (Council Decision 2005/387/JHA10), the EWS enables the rapid 
exchange of information on NPS, the assessment of risk and the application 
of existing control measures to NPS. Each Member State shares information 
on the manufacture of, trafficking in, use of, and of preparations containing 
NPS through its Europol National Unit and its representative in the Reitox 
Network. This information is then shared with Member States, the EC and the 
European Agency for the Evaluation of Medicinal Products (EMEA). A report 
is prepared and submitted  to the Council of the EU and if necessary, a risk 
assessment carried out by the EMCDDA. Within 6 weeks of the EC receiving 
the risk assessment report, the EC must present an initiative to the EU to 
place the substance under control, or if the EC doesn’t find that necessary, 
then one or more of the EU member states can present an initiative. Then, if 
the EU decides to place control measures on the new substance, it should do 
so no later than one year from the date of the decision.  By mid-2014, 
seventeen risk-assessments had been completed, as follows: 25I-NBOMe, 
AH-7921, MDPV, Methoxetamine, MBDB, 4-MTA, GHB, Ketamine, PMMA, 
2C-I, 2C-T-2, 2C-T-7, TMA-2, BZP, Mephedrone, 4-methylamphetamine (4-
MA) and 5-(2-aminopropyl)indole (5-IT). Of these, 11 have so far been placed 
under EU control. 
 
National responses 
 
6.5 Outside of Europe, several countries have taken action to control NPS at the 
local level, including Japan, New Zealand, Republic of Korea and the USA.  
 
6.6 In Japan, at the Tokyo level in 2005, then at the national level in 2007, new 
legislative powers were granted to allow control over NPS, prohibiting their 
advertising, supply and production (with penalties of up to 5 years in prison, or 
fines of up to 5 million Japanese Yen). Possession for personal use does not 
constitute an offence.  As at November 2012, 90 NPS were controlled under 
the 2007 law.  
 
6.7 In New Zealand, the 2005 Misuse of Drugs Amendment Act created a new 
schedule to control the manufacture and sale of new ‘restricted substances’ 
for which there was not yet enough evidence of potential harm to prohibit 
them completely.  BZP was placed on the schedule, but in 2008, on the basis 
of new evidence, it was placed in Schedule 3 (Controlled Drugs). In New 
Zealand a new Act came into force on 18 July 2013 which places the onus 
onto manufacturers to prove that their products pose a low risk of harm, prior 
to receiving approval which allows the products to be legally manufactured 
and sold (Wilkins et al, 2013). While the regulatory system was being 
developed, a number of interim retail and product licences had been granted 
for untested NPS. However, in May 2014, the NZ Government amended the 
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Act to remove all interim approved psychoactive products from the market 
until further testing confirms they present a low risk of harm to users. A critical 
assessment of the new regime by Wilkins (2014) concluded that the clinical 
trials required to test NPS would need to address the characteristics of 
recreational drug use including binge use, polydrug use, use by vulnerable 
populations and high risk modes of administration. 
 
6.8 In the Republic of Korea, drugs are controlled under the ‘Act on the Control 
of Narcotics’. Several NPS have been controlled under the Act since the mid 
2000s, and it was strengthened further in 2011 by the addition of a new 
‘temporary scheduling system’ which allows the Korean Food and Drug 
Administration to temporarily schedule NPS for a year (UNODC, 2013a).   
 
6.9 In the USA, the Controlled Substances Act (CSA) provides regulations for the 
manufacture, importation, possession, use and distribution of certain 
substances.  Temporary scheduling of NPS to avoid imminent hazard to 
public safety is also possible under the CSA. As well as the CSA, the USA 
has the ‘Federal Analogue Act’ which was set up to control substances not 
specifically listed in the CSA.  An ‘analogue’ drug is defined as a substance 
which is intended for human consumption and is structurally or 
pharmacologically substantially similar to, or is represented as being similar 
to, a Schedule I or Schedule II substance and is not an approved medication 
in the United States. Although other countries have adopted similar systems, 
it is acknowledged that the analogue system is not perfect, owing to (a) 
difficulties defining analogue drugs and (b) what to do with plant based 
substances that don’t meet condition (i) above (UNODC, 2013a).  
 
Other regulatory frameworks  
 
6.10 Several countries have introduced generic or analogue systems to control 
groups of similar substances to those individually listed, without the need to 
resort to legislative reform (e.g. UK, Hungary, Luxembourg, Italy, Ireland, 
Norway, USA). Many governments have also used ‘emergency scheduling’ to 
introduce temporary bans on NPS whilst the legislative process is being 
completed (e.g the UK, Denmark, Germany, Netherlands,  Australia, USA). 
Finally, other regulatory frameworks, such as medicine legislation and 
consumer safety regulations have been used, primarily to control the sale of 
NPS (UNODC, 2013a). 
 
6.11 In the UK, the government has control of substances under the Misuse of 
Drugs Act 1971. If a drug is causing sufficient concern, the UK Government 
(following consultation with the Advisory Council on the Misuse of Drugs 
(ACMD) can issue a Temporary Class Drugs Order for up to 12 months. This 
bans the import and supply of a substance but does not make possession a 
criminal offence. The ACMD then has 12 months to investigate and 
recommend classification if they consider there is sufficient evidence. In 2013, 
new categories of synthetic cannabinoids, methoxetamine and other 
compounds related to ketamine and phencyclidine were all made Class B 
drugs. ‘NBOMe’ and ‘Benzofury’ became subject to a Temporary Class Drug 
Order (TCDO) in June 2013 for a period of up to 12 months (Public Health 
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England, 2013c). As of 10 June 2014, they became fully controlled as Class A 
and Class B drugs respectively (Home Office, 2014). 
 
6.12 The UNODC’s review of approaches recommended a global Early Warning 
System in order to inform Member States about the emergence of NPS on the 
market. This is now in place, entitled the ‘Early Warning Advisory’ and 
provides provides: a selected bibliography on NPS aimed to inform Member 
States, the scientific community and other users on recent available sources 
on methods for the analysis and identification of NPS; selected articles on the 
toxicology/pharmacology of NPS, use and treatment; as well as identified 
legislative responses to counteract the challenge of NPS (UNODC, 2014b). 
Alternative approaches to scheduling an ever larger number of substances 
have had some success in lowering NPS prevalence rates. However, the 
potential for supply and demand to simply shift to new substances must be 
kept in mind. In the long run, some form of common approach to NPS at the 
international level would be desirable.  Although various approaches may 
have worked to some degree in individual countries, there are now multiple 
separate control regimes, leaving loopholes in the control system at the global 
level which drug manufacturers can exploit (UNODC, 2013b). 
 
 
Prevention 
 
6.13 To date, measures to reduce the demand for, and supply of, NPS have largely 
focussed on control measures, with countries using a mixture of market 
regulations, existing drug control legislation and new laws (see above). In 
addition, providing warnings on the adverse health effects of NPS is one of 
the activities of the Early Warning System that provides added value to the 
Member States. In 2012, the EMCDDA issued health alerts for seven NPS 
and one ‘legal high’ product (see report for more details) (EMCDDA, 2013b). 
 
6.14 Interest is now growing in addressing the wider issues surrounding NPS, 
especially the need to understand the potential health and social impact of 
these drugs and to identify appropriate demand reduction strategies. A key 
recommendation from the ACMD report on NPS (2011) was that strategies 
are implemented to reduce the demand for NPS by including NPS in 
substance misuse education in schools and developing targeted prevention 
initiatives (ACMD, 2011). Among new approaches being studied are 
innovative internet-based prevention programmes and the delivery of targeted 
school based prevention messages (EMCDDA, 2012).   
 
6.15 In the UK, ‘legal high’ facts, emergency help and drug treatment information 
are provided by ‘talk to Frank’’. In Ireland prevention and harm-reduction 
information on new drugs has been in circulation since 2010. In Poland, 3 
prevention campaigns were launched in 2008: a web-based information 
campaign; meeting between parents and schools; and a universal prevention 
programme targeting the school population aged 15-18. The Recreational 
Drugs European Network Project (ReDNet) was a multi-site project funded by 
the EU’s Health Programme to improve the level of information available to 
young people and professionals about the health risks associated with the use 
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of NPS. An evaluation of the project concluded that web-monitoring activities 
are essential for mapping the spread of NPS and that technological tools can 
be used successfully in specific prevention programmes. The involvement of 
multi-disciplinary international partnerships was, and continues to be, 
fundamental for responding to the challenges posed by NPS (Corazza et al, 
2013).  
 
6.16 In Scotland work has been done to update the prevention messages on NPS, 
including updating the information available on the Know the Score website, 
and the development of an information resource, by Police Scotland, on NPS 
for high school children through the Choices for Life initiative.  
 
6.17 In recognition of the growing problem in Wales, the Advisory Panel on 
Substance Misuse (APoSM) established a Psychoactive Substances Sub 
Group, which consisted of a range of stakeholders, to advise how to respond 
to this issue. The Sub Group recommended a number of preventative and 
harm reduction approaches which has resulted in the following:  
 Working closely with partners to develop a range of education and prevention 
materials in addition to carrying out a national campaign in conjunction with 
the national helpline DAN 24/7, Real Radio and the Welsh Rugby Union. 
 Developing a warning system whereby any alerts received from across the 
UK are distributed via the Chief Medical Officer. The purpose of these alerts is 
to circulate appropriate information to relevant clinical services, and to ask if 
any services – including Emergency Departments and ambulance teams - are 
aware of related cases or additional intelligence (Welsh government, 2013).  
 
 
Treatment  
 
6.18 A key recommendation from the ACMD report on NPS 2011 was for treatment 
to be provided for those with acute problems (eg within A&E) and dependency 
(ACMD, 2011). However, to date treatment for NPS users who seek formal 
help is primarily supportive and there is limited information on what constitutes 
appropriate psychosocial treatment for this group. In the UK, a 
multidisciplinary specialist clinic for users of club drugs has been piloted, 
offering a range of responses including: brief interventions; pharmacological 
therapies; and planned care support, demonstrating good retention and 
outcomes (EMCDDA, 2012). The National Treatment Agency states that, with 
new substances emerging all the time, treatment services must remain 
vigilant and adaptable (National Treatment Agency, 2012).  
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7 EVIDENCE GAPS 
 
Key Findings 
The following are needed in order to inform future policy responses to NPS 
(both in Scotland and more widely): 
 A full assessment of what is known about the scale and patterns of NPS use. 
 Exploration of the nature of the relationship between the new drugs market 
and the established market in controlled drugs. 
 An examination of the short and longer term health impacts of using NPS, 
and other outcomes. 
 A systematic review of  the outcomes of the various control systems. 
 Analysis of how current interventions to prevent substance misuse and 
harms may be used for NPS, and consideration of possible new approaches. 
 Evidence of what constitutes appropriate psychosocial treatment for NPS 
users. 
 
7.1 Despite recent concerns about the growth in the number and use of NPS, 
there remain significant gaps in our knowledge about these drugs that need to 
be addressed to inform future policy responses. The need for further research 
into NPS was highlighted in the 2011 report of the Advisory Committee on the 
Misuse of Drugs, and reflected in the Action Plan of the UK Government’s 
2012 Annual Review of the Drug Strategy.  In terms of more specific 
information gaps/ research needs, the following are identified in the literature: 
 
 
Prevalence of use 
 
7.2 There are large gaps with regard to prevalence data which need to be 
addressed to improve the basis for decision making (UNODC, 2013b). An 
assessment is needed of what is known about the patterns of use of NPS  in 
the UK, including the scale and types of use, demographic patterns of use, 
predictors of use, motivations and pathways to use, use with other 
substances, settings of use, concurrent health-related and other behaviours, 
and outcomes of use, particularly of acute harm or toxicity, and dependence. 
It is important, where possible, that self-reported use should be confirmed with 
objective measures (e.g. wastewater analysis (Archer et al, 2012) and data 
from Accident and Emergency records/ poison information services , with 
content of NPS confirmed with analytical data (NIHR, 2013). 
 
 
Supply 
 
7.3 There is a need to analyse and respond to the interplay between the new 
drugs market and the established market in controlled drugs (EMCDDA, 
2013a). 
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Health and other implications 
 
7.4 Research on the health implications of most NPS is very limited. The ACMD 
(2011) recommended that resources are provided for research on the 
chemistry, pharmacology, acute harm (toxicity) and social harms of NPS. 
There are no comprehensive scientific studies on their toxicity and most 
studies are based on work in animals, fatal poisonings in humans, or 
observations in intoxicated patients. Toxicity, abuse liability and risks 
associated with long term use in particular remain unknown.  Further research 
is needed on the short and long term health risks and addiction potential of 
these substances (UNODC, 2013a).  
 
7.5 Regular data and information are needed from a range of sources (including 
GPs, drug services, the ambulance service, Emergency Departments, in-
patient wards, NRS death records)  to understand the characteristics of those 
using and suffering adverse health consequences, as well as trends in  NPS 
used and how they are used (Corkery, J., 2013). However, there is an issue 
with data not being routinely collected by these sources, or in a standardised 
way. Often these problems are caused by a lack of local resources to collect 
the data, the absence of protocols, legal/ ethical issues about sharing data 
between agencies, and insufficient resources for those investigating NPS 
characteristics – neurobiologists, pharmacologists, toxicologists, etc; and 
those monitoring adverse health consequences (Corkery, J. 2013). 
 
 
Regulation 
 
7.6 A systematic review of the outcome of various systems should be made with a 
view to improving the control system at the international level (UNODC, 
2013b). The Home Office is currently leading a review of the UK’s legislative 
response to maximise its impact and improve the operational response to the 
NPS market. This will draw on expertise from law enforcement, local 
authorities, academia, media and social science. The review will be informed 
by international approaches as well as other evidence, and is due to report in 
2014. 
 
 
 Prevention and Treatment 
 
7.7 Analysis is required of how current interventions to prevent substance misuse 
may be used for NPS, and consideration of possible new approaches (NIHR, 
2013).There is also limited information on what constitutes appropriate 
psychosocial treatment for this group. (EMCDDA, 2012). There is also a need 
to better understand how to deal with users who become unwell in 
recreational settings and when to call an ambulance (EMCDDA, 2012).  The 
NIHR (2013) states that there is a need to bring together current knowledge, 
possibly supplemented with further research, to build understanding of 
different target populations for interventions. Possible interventions, and 
approaches to preventing uptake and reducing use and harm of novel 
psychoactive substances should be considered. 
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